Drug intelligence / Profile preview

VE-5953

Development stage: Unknown
Lead developer: Verseon
Modality: Small Molecules

Overview

VE-5953 is a small molecule drug candidate developed by Verseon. It acts as an inhibitor of CD73 (ecto-5'-nucleotidase), an enzyme involved in the production of extracellular adenosine, which can suppress anti-tumor immune responses. By inhibiting CD73, VE-5953 aims to restore immune response against CD73-positive cancers and is being investigated for its potential use in oncology, specifically for neoplasms. As of June 2025, the compound remains at the discovery or preclinical stage and has not entered clinical trials[1][2][3][8].

Targets

NT5E (Cluster of Differentiation 73)

Beyond the preview

Go deeper on VE-5953.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VE-5953.

Explore the full profile